Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Selank

Selanc, TP-7

Quick Stats
Studies 114
Trials 11
Score 2
2006 pubmed

Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight.

Czabak-Garbacz. Róza R; Cygan. Beata B; Wolański. Lukasz L; Kozlovsky. Igor I

Key Findings

  • TP-7 (a tuftsin analogue) produced a significant anxiolytic effect starting on day 2 of treatment.
  • The anxiety‑reducing effect lasted throughout a four‑week testing period.
  • TP-7 did not cause any increase or decrease in body weight in the rats.

Practical Outcomes

  • For biohackers, TP-7 shows promise as a potential fast‑acting anxiety‑reducer, but the evidence is limited to rodents and requires human testing. It suggests that, if similar effects occur in people, low‑dose daily administration might be explored for anxiety without weight side‑effects, though safety and dosing remain unknown.

Summary

A study in rats found that daily injections of the peptide TP-7 lowered anxiety-like behavior within two days and kept it low for at least four weeks, while not changing the animals' body weight.

Abstract

TP-7 is a synthetic analogue of tuftsin. It has a structure of tuftsin, to which three natural L-amino-acids Pro-Gly-Pro are attached. This heptapeptide improves learning and memorization and causes antidepressant and anxiolytic effect. It is possible to use TP-7 in the future to optimize cognitive functions and as a potential new anxioselective, fast-acting and easy-dosed drug. Therefore, it was purposeful to study such properties of the heptapeptide as its influence on anxiety-fear and body weight under a long-term treatment regimen. The experiment was performed on 24 preselected Wistar rats with the use of Rodina's method. There were three experimental groups of animals with high initial emotional reactivity: passive control group (P), active control group (A, receiving distilled water) and group treated with TP-7 at the dose of 0.3 mg/kg (T). The rats of A and T groups received intraperitoneal injections every day. The experiments were conducted 15 min after the administration of the drug, one and two days after initial testing day, then 1, 2, 3 and 4 weeks after that. The heptapeptide reduced the anxiety-phobic states significantly starting from the second day of drug application. The observed effects persisted throughout four weeks of the experiment, which confirmed effective long-term anxiolytic properties of the heptapeptide. TP-7 did not cause any changes in the body mass by itself.

Study Information

Provider

pubmed

Year

2006